Bristol Myers Squibb Scoops Up Schizophrenia Player Karuna Therapeutics In Massive $14B Deal

Zinger Key Points
  • Bristol Myers values Karuna Therapeutics' equity at about $14 billion.
  • Karuna is focused on developing treatments for psychiatric and neurological conditions.

On Friday, Bristol Myers Squibb & Co BMY agreed to acquire Karuna Therapeutics Inc KRTX for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 billion net of estimated cash acquired

Karuna is focused on developing treatments for psychiatric and neurological conditions. Karuna's lead asset, KarXT (xanomeline-trospium), is an antipsychotic. 

A New Drug Application (NDA) for KarXT for schizophrenia in adults was accepted for review by the FDA, with a Prescription Drug User Fee Act date of September 26, 2024. 

KarXT is also in registrational trials both for adjunctive therapy to the existing standard-of-care agents in schizophrenia and for the treatment of psychosis in patients with Alzheimer's disease. 

Bristol Myers Squibb believes KarXT represents a significant revenue contribution opportunity. 

Also Read: Bristol Myers Squibb's Mega $8.4B Oncology Bet - Secures Exclusive License With SystImmune.

Bristol Myers Squibb also sees potential from Karuna's early-stage and pre-clinical pipeline.

  • Schizophrenia: KarXT is expected to launch in late 2024 in the U.S. as a treatment for schizophrenia in adults. There are approximately 1.6 million people treated for schizophrenia in the U.S.
  • Adjunctive schizophrenia: A registrational clinical trial is currently underway evaluating KarXT as adjunctive treatment with the current standard of care agents for schizophrenia, with data expected in 2025.
  • Alzheimer's disease psychosis: Registrational clinical trials are currently underway evaluating KarXT for Alzheimer's disease psychosis, with data expected in 2026. More than 6 million people are living with Alzheimer's disease in the U.S. 
  • Additional indications: Bristol Myers Squibb believes KarXT also has potential in additional indications, including Bipolar I disorder, which impacts approximately 1.4 million people in the U.S., and Alzheimer's disease agitation.

The transaction is expected to be dilutive to Bristol Myers' non-GAAP EPS by approximately $0.30 in 2024.

The transaction is expected to close in the first half of 2024.

Price Action: KRTX shares are up 48.80% at $320.30, and BMY stock is down 0.41% at $51.05 during the premarket session on the last check Friday.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechLarge CapM&ANewsHealth CareMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!